Few studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study assessed these outcomes in newly diagnosed patients with FL and patients with FL with early disease progression. Rituximab-based regimens predominated across lines of therapy; however, utilization of rituximabbased regimens was lower among early versus non-early progressors. Early progressors also had worse overall survival compared with non-early progressors. Background: Few studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed patients with FL in routine clinical care. Patients and Methods: A retrospective study was conducted in newly diagnosed patients with FL from Humedica, a large United States electronic medical record database, from January 1, 2008 to July 31, 2015. Patients were followed from treatment initiation until death, loss to follow-up, or end of study (September 30, 2015). Treatment patterns were assessed in the follow-up period. Progression-free survival (PFS) and overall survival (OS) at 2 years were evaluated in the overall population using Kaplan-Meier analyses. OS was also compared between patients with and without evidence of disease progression within 2 years following first-line therapy (ie, early progressors vs. non-early progressors). Results: A total of 1346 patients were included in the study, with most patients receiving rituximabbased regimens. Fewer early progressors received rituximab-based regimens. Across all lines, combination therapies predominated, particularly bendamustine þ rituximab. Following first-line therapy, OS was 86.9% at 2 years, and median OS was not reached. Two-year PFS after first-line therapy was 64.6%, and median PFS was 48.1 months (95% confidence interval, 39.4-58.4 months). OS at 2 years was 76.8% among early progressors versus 90.4% among non-early progressors (P < .001); the median OS was not reached in both groups. Conclusion: In routine clinical practice, rituximab-based regimens predominated; however, utilization of these regimens differed among early and non-early progressors. The assessment of survival outcomes also highlights the negative impact of early progression on OS in the rituximab-era.
Introduction
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 15% to 20% of adult NHLs. [1] [2] [3] The median age at FL diagnosis is 65 years, and most patients present with advanced stage disease. 4 FL is a heterogeneous disease, with a variety of prognostic indicators, and may transform over the disease course to higher grade NHL, most commonly diffuse B-cell lymphoma (DLBCL), 7 with a suggested cumulative rate of transformation of 3% per year. 8 Significant improvements have been made in FL therapy over the past several decades, particularly with the introduction of rituximab, which has impacted the natural history of the disease and its treatment paradigm. 1, 4 Use of rituximab, as a single agent or in combination with chemotherapy in first-line therapy, has led to significant improvements in median time to progression and response rate. 1, [9] [10] [11] [12] [13] [14] [15] Rituximab maintenance therapy has also been reported to improve event-free survival in chemotherapy-naive patients who had initially responded to a rituximab-based induction regimen, although this benefit did not result in an overall survival (OS) advantage. [16] [17] [18] Despite these improvements, there is no standard therapy for relapsed/refractory FL; in fact, the National Comprehensive Cancer Network Guidelines do not provide specific recommendations after second-line therapy. 19 Front-line regimens are an option in this setting, depending on prior response and remission duration, with treatment selection generally based on individual patient and tumor characteristics. 5 Additionally, approximately 20% of patients with FL experience disease progression within 2 years of front-line therapy and have more aggressive disease and poorer clinical outcomes, even with maintenance rituximab usage. 7, [20] [21] [22] [23] This consistent observation across studies suggests that these patients may have a different disease biology and warrant alternative therapies, either initially or at the time of relapse. 21 Few studies have reviewed FL treatments beyond the first-line setting. Treatment patterns and outcomes of patients with early disease progression have also not been extensively studied. Therefore, we conducted a retrospective analysis of a cohort of patients with FL receiving routine clinical care in the United States (US) in order to evaluate treatment patterns in the first-, second-, and thirdline settings, and to assess OS and progression-free survival (PFS). We further evaluated OS following frontline treatment in patients progressing within 2 years following first-line therapy ("early progressors"). 7, 21 Patients and Methods
Study Design and Patient Identification
In this retrospective cohort study, the Humedica electronic medical record (EMR) data from January 1, 2008 through September 30, 2015 was analyzed. Humedica represents a large group of comprehensive integrated healthcare delivery networks (IDNs) within the US, offering patients a multitude of services, including acute inpatient and outpatient care. These organizations provide care for patients from all 50 states and account for over 140,000 providers, 6500 clinics, and 600 hospitals.
The target population was adult patients (! 18 years) with a diagnosis of FL between January 1, 2008 and July 31, 2015; FL diagnosis was defined as the presence of ! 1 inpatient record with an FL diagnosis code (International Classification of Diseases codes: 202.xx; ICD-10 codes: C82.xx) or ! 2 outpatient records with a FL diagnosis code that are ! 60 days but within 1 year apart. The first record of FL during this period served as the index diagnosis date. The 12-month period before the index diagnosis date was defined as the baseline period, and the follow-up period consisted of ! 60 days from the index diagnosis date; however, patients who died within this 60-day period were followed for < 60 days. Patients were followed until death, transformation to DLBCL (for OS only), loss to follow-up, or end of the study (September 30, 2015) .
To be included in the analyses, patients were also required to have continuous care in the EMR in the baseline period and in the follow-up period, and to receive treatment within a Humedica IDN. Patients were excluded if they had evidence of FL or other primary cancer(s) (including DLBCL or other NHL) or metastatic disease in the baseline period; evidence of any chemotherapy/chemoimmunotherapy or stem cell transplantation (SCT) in the baseline period; receipt of only SCT in the follow-up period or SCT monotherapy as first-line of therapy (LOT); and inconsistent data (date of death reported prior to index diagnosis date). Evidence of SCT within the EMR was based on a natural language processing system; the date of SCT was the date of the healthcare provider's note with the SCT record.
Baseline Characteristics
Baseline demographics collected on the index diagnosis date included age, race/ethnicity, gender, year of FL diagnosis, payer type, and geographic region. Baseline clinical characteristics collected in the 12-month baseline period were Charlson comorbidity index (CCI) and the individual comorbidities used to define the CCI. In addition, a frailty index was also generated using the Jen Frailty Index (JFI) algorithm. The JFI is a risk-scoring tool that uses 13 condition categories, which encompasses nearly 1800 diagnoses found to be significantly related to concurrent or future need for long-term care services. 24 The 13 categories include minor ambulatory limitations, severe ambulatory limitations, cognitive developmental disability, chronic mental illness, dementia, sensory disorders, self-care impairment, syncope, cancer, chronic medical disease, pneumonia, renal disorders, and systemic disorders (eg, septicemia).
Treatment Patterns
Treatment patterns in the front-line and relapsed/refractory settings, including time to treatment initiation, duration of therapy, treatment regimens, and supportive care use, were assessed in the follow-up period. All agents initiated within 90 days following the day of the first infusion or fill date for a chemotherapy agent following the index diagnosis date constituted the first-line treatment regimen. Time to initiation of first-line therapy was defined as the period from index diagnosis date to the first evidence of chemotherapy in the follow-up period. A subsequent LOT was defined as treatment initiated after ! 180 days following the runout date of all agents in the prior LOT, or addition or substitution of a new agent in the prior LOT after 90 days. Duration of an LOT was defined as the time from initiation of an LOT to the last day of therapy for the LOT.
SCT was considered part of the preceding LOT if it occurred within 365 days after initiation of that LOT and the next LOT had not started. Any agent given within 7 days prior to SCT was considered part of the LOT. Single-agent rituximab initiated within 90 days of the SCT was considered maintenance therapy and was not evaluated separately; rather, this was included as part of the same LOT as the SCT. A subsequent LOT began with the administration of an agent other than rituximab.
Supportive care use was also captured in the follow-up period. This was defined as the use of erythrocyte/platelet transfusions; thrombopoietic-, erythropoietic-, and granulocyte colonystimulating agents (G-CSFs) (ie, filgrastim, pegfilgrastim, sargramostim, Tbo-filgrastim); hydroxyurea; antifungals; and pain medications. 
Survival Outcomes
Survival outcomes following the initiation of the first-line therapy were evaluated. FL progression was defined as transformation to DLBCL, initiation of another LOT, or receipt of supportive care other than pain or antifungal medications > 30 days following the end of LOT. PFS was defined as time to progression or death; and OS was defined time to death by any cause.
Subgroup of Interest
OS was also assessed among early progressors versus non-early progressors. Early progressors was defined as patients with evidence of progression (eg, DLBCL transformation, relapse/progression as defined by receipt of supportive care, and initiation of subsequent LOT) within 2 years following first-line therapy.
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Statistical Analysis
Categorical measures were presented as counts and percentages of patients in each category, whereas continuous outcomes were presented as means, standard deviations (SDs), medians, and interquartile ranges (IQRs). Kaplan-Meier analyses was used to assess median OS and PFS, as well as OS and PFS at 2 years and over the entire follow-up period in the overall population. Median OS and OS at 2 years and over the entire follow-up period were compared between early progressors and non-early progressors using log-rank tests.
Analyses were conducted using SAS version 9.4 (SAS Institute; Cary, NC).
Results
A total of 10,211 patients with a diagnosis of FL between January 1, 2008 and July 31, 2015 were identified from the Humedica database ( Figure 1 ). After the study inclusion and exclusion criteria were applied, we identified 3756 newly diagnosed patients with FL. Of these, 1346 received first-line therapy, and were included in our analyses.
The median age of the cohort was 67 years (mean, 65.4 years; SD, 12.8 years; range, 18-85 years), and 47.7% were male ( Table 1 ). The majority (88.7%) of patients were Caucasian. The CCI score was 1 in 21.1% of the patients, and 16.6% had a CCI score of 2þ. Of the CCI conditions, diabetes (14.5%), chronic obstructive pulmonary disease (11.2%), and peripheral vascular disease (6.8%) were most common. The mean JFI was 2.7 (SD, 2.0); 50.1% had low-risk frailty, 40.3% had medium-risk frailty, and 9.7% had high-risk frailty.
Of the 1346 patients, 279 (20.7%) were early progressors (ie, evidence of progression within 2 years following initiation of firstline therapy). The median age of early progressors and non-early progressors were similar, but a higher proportion of the early progressors were male (53.0% vs. 46.3%). Moreover, there were more early progressors with baseline CCI score of 1 or 2 compared with non-early progressors (42.3% vs. 36.5%). Additionally, the prevalence of the individual Charlson comorbidities was slightly higher among patients with early progression. Similarly, the mean JFI was slightly higher among patients with early progression. 
First-line Treatment Patterns
The median time to initiation of first-line therapy was 1.3 months (IQR, 0.5-5.9 months; range, 0.0-81.1 months) ( Table 2) . More patients initiated combination (61.4%) versus single-agent (38.6%) chemotherapy, with most (90.6%) regimens being rituximab-based. The majority (94.3%) of combination therapies were rituximab-based, with bendamustine þ rituximab (43.8%); rituximab þ cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (25.5%); and rituximab þ cyclophosphamide, vincristine and prednisone (R-CVP) (12.8%) being most commonly utilized. Among the single-agent regimens, rituximab (85.8%) was most common. Receipt of SCT was not common in the first-line setting (0.7%).
More patients in the early progressor group received first-line combination therapy compared with the non-early progressor group (69.9% vs. 59.1%) ( Table 2 ). Use of bendamustine þ rituximab was less common among early progressors than non-early progressors (22.6% vs. 50.4%). However, use of R-CHOP and R-CVP was more common among early progressors than non-early progressors (29.7% and 16.4% vs. 24.2% and 11.7, respectively). Overall, the use of rituximab-based combination regimens was Supportive care was also used during the first-line therapy (Table 2) , with 37.6% of patients receiving G-CSFs and 8.5% receiving red blood cells or platelet transfusions. More early progressors received G-CSFs (43.7% vs. 36.0%) and transfusion (12.9% vs. 7.3%) than non-early progressors.
The median duration of first-line therapy was 4.3 months (IQR, 1.7-10.4 months; range, 0-81.5 months) for the overall population. It was 3.2 months (IQR, 1.2-5.3 months; range, 0-20 months) for early progressors and 4.9 months (IQR, 2.2-13.6 months; range, 0-81.5 months) for non-early progressors.
Second-line Treatment Patterns
A total of 201 patients received second-line therapy, which was single-agent in 34.3%, and combination chemotherapy in 65.7% (Table 3) . Second-line regimens were similar to first-line regimens, with rituximab (55.1%) remaining the top single agent, whereas bendamustine þ rituximab (39.4%) and R-CHOP (9.8%) remained the top combinations. Rituximab was a component of 88.6% of all combination regimens. The proportion of patients who received SCT remained low at 1.5%.
Among the early progressors (n ¼ 150) and non-early progressors (n ¼ 51) that received second-line therapy, the use of combination therapy was similar among the 2 groups (65.3% vs. 66.7%, 
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e178 -Clinical Lymphoma, Myeloma & Leukemia April 2019 respectively). The combination regimens were mainly rituximabbased among the early and non-early progressors (85.7% vs. 97.1%, respectively) ( Table 3 ). The most common combination regimens among the early progressors and non-early progressors were bendamustine þ rituximab and R-CHOP (36.7% and 9.2% vs. 47.1% and 11.8%, respectively). Treatment with supportive care was also maintained in secondline therapy (Table 3 ). Although the proportion of patients receiving G-CSFs remained similar to that observed in first-line therapy (37.3%), the proportion of patients receiving transfusions (16.9%) and antifungals (17.4%) increased. Although the proportion of patients treated with G-CSFs was similar among the early progressors and non-early progressors (37.3% each), fewer early progressors received transfusion compared with non-early progressors (14.7% vs. 23.5%).
The median duration of second-line therapy was 3.6 months (IQR, 1.4-6.1 months; range, 0-46 months) for the overall population; 3.6 months (IQR, 1.4-6.3 months; range, 0.0-46.0 months) for early progressors and 3.5 months (IQR, 1.2-5.8 months; range, 0.1-28 months) for non-early progressors.
Third-line Treatment Patterns
Only 45 patients received third-line therapy (early progressors, n ¼ 38 and non-early progressors, n ¼ 7) (Table 4) . In this setting, 35.6% received a single agent (early progressors, 34.2% and nonearly progressors, 42.9%), whereas 64.4% received combination chemotherapy (early progressors, 65.8% and non-early progressors, 57.1%). Rituximab (31.2%) was the most common single agent; bendamustine þ rituximab (31.1%) was the most common combination. The proportion of patients who underwent SCT increased to 11.1%.
The use of supportive care continued during the third-line therapy, with 26.7% of patients receiving antifungals, 33.3% of patients receiving transfusions, and 42.2% of patients receiving GCSFs. The median duration of third-line therapy was 2.8 months (IQR, 1.4-4.7 months; range, 0.7-26.2 months).
Survival Outcomes After First-line Treatment
In the unadjusted Kaplan-Meier analysis following first-line therapy, OS was 91.9% at 1 year, 86.9% at 2 years, and 68.1% at the end of follow-up (Figure 2 ). The median OS was not reached When comparing early and non-early progressors, unadjusted Kaplan-Meier analysis showed that following first-line therapy, OS was 89.9% among early progressors versus 92.5% among nonearly progressors (P ¼ .2617) at 1 year and 76.8% among early progressors versus 90.4% among non-early progressors (P < .001) at 2 years (Figure 3) . At the end of follow-up, OS was 59.9% among early progressors versus 69.8% among non-early progressors (P < .001). The median OS was not reached for either group of patients. 
Discussion
This study evaluated treatment patterns in the front-line and relapsed/refractory settings, as well as survival outcomes in newly diagnosed patients with FL. We also evaluated the subgroup of early progressing patients, based on prior publications reporting that 20% of patients with FL relapse within 2 years of the first-line therapy, irrespective of rituximab usage. 21 This subgroup of early progressors constituted 23% of our study population. Not surprisingly, treatment regimens in the front-line and relapsed/ refractory settings were mainly rituximab-based. Combination therapy was more common than monotherapy, and the proportion of patients receiving monotherapy versus combination therapy remained relatively similar across all 3 lines of therapy. Rituximab was the most common monotherapy utilized in all lines of therapy. Combination therapy regimens was predominately bendamustine þ rituximab in all lines of therapy, followed by R-CHOP and lastly R-CVP. Comparing early and non-early progressors, treatment with rituximab-based therapy was less common among early versus non-early progressors. In first-line therapy, more patients with early progression received combination therapy, particularly R-CHOP and R-CVP, whereas bendamustine þ rituximab was common among non-early progressors. In second-line therapy, bendamustine þ rituximab was the top regimen used in both patient groups.
Other studies have evaluated front-line treatment patterns in patients with FL, but treatment patterns among patients with relapsed/refractory disease are not common, whereas such data for early FL progressors have not been published. In the National LymphoCare Study, first-line treatment regimens, similar to our findings, were also mainly rituximab-based; combination regimens dominated, particularly R-CHOP, followed by R-CVP, and monotherapy was mainly rituximab. 21, [25] [26] [27] These studies, however, were conducted prior to the approval of bendamustine. The emergence of bendamustine þ rituximab as the most common combination regimen in our study aligns with results of more recent clinical trials that demonstrated significantly improved PFS and fewer infectious and hematologic toxicities in patients treated with bendamustine þ rituximab, compared with patients treated with R-CHOP. 28 Our study provides a contemporary view of FL treatment patterns in the front-line setting and beyond, as well as those for early progressors. Our finding that similar regimens are used across multiple lines of therapy highlights a need for newer therapies.
With changes in the treatment landscape for FL, it is important to evaluate survival outcomes in the real-world setting using current data. In our study, we reported outcomes on all treated newly diagnosed patients with FL receiving a variety of regimens. Following first-line therapy, PFS and OS in the overall treated population were 64.6% and 86.9%, respectively, at 2 years and 32.4% and 68.1%, respectively, at the end of follow-up. The median OS was not reached, whereas the median PFS was 48.1 months. We also found that early progressors had lower rate of survival at 2 years (76.8% vs. 90.4%; P < .001) and at the end of follow-up (59.9% vs. 69.8%; P < .001) compared with non-early progressors; the median OS was not reached for either group.
The benefit of rituximab in prolonging OS and PFS of FL has been well-established, making it the cornerstone of therapy in these patients. 29 The high survival rate observed in our study aligns with previously reported studies, especially in the rituximab era. 29, 30 With regard to survival outcomes among early progressors, our results are also similar to that of the pooled analysis of 13 prospective clinical trials that validated early progression as a robust indicator of poor FL survival. 31 In this study, male gender, poor performance status, high FL International Prognostic Index (FLIPI) score, and elevated baseline beta 2 microglobulin were also identified as predictors of early death and progression. 31 Our results are also similar to those of the National LymphoCare Study, which is a prospective, multicenter registry of FL. 21 In this study, which compared OS among patients with and without early progression who received first-line R-CHOP, the OS at 2 years (68% vs. 97%) and at 5 years (50% vs. 90%) were lower among patients with early progression. 21 This study also adjusted for FLIPI score, finding that the higher risk of death still remained for patients with early progression. 21 They found similar results in an exploratory analysis, including only patients that received R-CVP and rituximab þ fludarabine. 21 These results are comparable with our findings. However, the 2-year OS was shorter in our study, likely because we included all patients regardless of the treatment received. As not all patients receive R-CHOP in first-line therapy, our study provides a comprehensive view of OS for patients in a real-world setting, regardless of the initial therapy.
Our study has limitations that should be considered when interpreting the results. First, there are those limitations inherent to any retrospective study. To ensure patients are newly diagnosed and have complete data during the study period, we excluded patients who did not meet the required minimum baseline and follow-up duration or were not treated in the IDN. Patients who truly have a new diagnosis of FL and were excluded solely for these reasons could have been different from the patients that remained in the study. It is possible that all relevant characteristics were not captured through the use of diagnosis codes. Detailed clinical information, such as the FLIPI risk factors, genetic mutation information, World Health Organization pathologic grade, and tumor stage, were not captured. Moreover, early progression was defined based on time to progression and could have potentially misclassified patients. Finally, because few patients received third-line therapy, the observed treatment patterns might differ in a large sample.
Despite these limitations, our study adds to the body of literature on current treatment patterns in routine clinical practice for first-, second-, and third-line FL therapy. Although treatment regimens were mainly rituximab-based, fewer patients with early progression received rituximab-based regimens. Bendamustine þ rituximab was the predominant combination regimen, followed by R-CHOP and R-CVP, and differences in the utilization of these regimens were observed among early and non-early progressors. The assessment of survival outcomes also highlights the negative impact of early progression on OS in the rituximab era.
Clinical Practice Points
The introduction of rituximab has impacted the natural history of FL and its treatment paradigm. Treatment guidelines recommend use of single-agent rituximab or in combination with chemotherapy in the frontline setting for treatment of symptomatic, advanced stage disease; however, there remains no standard of therapy for relapsed/refractory FL. Studies have also reported that approximately 20% of patients with FL experience disease progression within 2 years of front-line therapy and have more aggressive disease and poorer clinical outcomes. We evaluated treatment patterns and survival outcomes following first-line therapy among newly diagnosed patients with FL in routine clinical practice. OS was compared between patients with and without early disease progression following first-line therapy (ie, early progressors vs. non-early progressors). Our results showed that most patients received rituximab-based regimens in the first-, second-, and third-lines of therapy; however, fewer patients with early progression received rituximabbased regimens compared with non-early progressors. Although the OS rate following first-line therapy was high in this FL cohort, significant differences were observed between early and non-early progressors (76.8% vs. 90.4% at 2 years; P < .001 and 59.9% vs. 69.8% end of follow-up; P < .001). Our study adds to the body of literature on current FL treatment patterns in routine clinical practice for first-, second-, and thirdlines of therapy. Also, the assessment of survival outcomes highlights the negative impact of early progression on OS in the rituximab era. Further research is warranted to better understand factors correlated with early progression, including those leading to front-line treatment selection in patients with FL. 
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